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Very aggressive gastric adenocarcinoma with rare osteoclast — like giant 
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Extraskeletal carcinomas with osteoclast-like giant cells (OGC) constitute a rare type of malignant tumors, usually 
located in the pancreas, gall bladder, breast and kidney. Histologically they are characterized by the presence of mul-
tinucleated giant cells that resemble osteoclasts mixed with poorly differentiated adenocarcinoma cells. This paper 
reports a case of primary gastric adenocarcinoma with osteoclast-like giant cells in a 75-year-old woman who suffered 
from epigastric pain, nausea, vomiting and weight loss. Histological examination of the tissue obtained during initial 
surgery (subtotal palliative Billroth II resection) revealed poorly differentiated adenocarcinoma with an infiltrate of 
osteoclast-like giant cells and no EBV immunostaining (non-lymphoepithelioma-like carcinoma, stage pT4aN3a). The 
tumor progressed rapidly with extensive perigastric involvement, infiltration of the paraaortic lymph nodes and the 
head of the pancreas. Poor general condition (WHO 3) prevented postoperative chemotherapy. The patient died 5 
months after surgery due to rapid relapse. There is still a lack of knowledge to determine the prognosis for patients 
with OGC carcinomas. In this study, we report a case of gastric adenocarcinoma with OGC and review the previously 
published literature clinical and pathologic data on this rare neoplasm.
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Introduction
Adenocarcinomas with osteoclast-like giant cells, that 
are typical for osseous neoplasms, are extremely rare tumors 
with usually slow growth, a relapse rate of 50% after surgery, 
and low metastatic potential. Undifferentiated carcinomas 
with OGC were first described by Rosai in 1968 and classi-
fied by WHO in 2000 [1]. According to the literature, these 
tumors are often discovered in the breast [2], pancreas [3], 
endometrium [4], gallbladder [5]osteoclast-like giant cells 
(OGCs, thyroid [6] and lungs [7]. Until the present, only few 
cases of gastric adenocarcinomas with OGC, usually poorly 
differentiated have been reported, mostly in men (Tab. I). 
They were located mainly in the gastric cardia or corpus.
Case description
A 75-year old female was admitted to the Surgical 
Department in January 2013 reporting upper abdominal 
pain, nausea and vomiting. There was no history of hema-
tochezia or melena, but she had lost 6 kg in weight in 2 
months. Physical examination revealed mild tenderness 
in the epigastric region of the abdomen. Laboratory tests 
showed anemia (Hb 7.8 mmol/l) with iron deficiency (Fe 
8.1 µmol/l). An abdominal CT scan demonstrated a large 
mass 15 × 10 cm infiltrating the lesser curvature of the 
stomach, antrum and duodenum without lymph node 
involvement. Esophagogastroscopy revealed an ulcerative 
lesion of 5 cm diameter in the antrum as well as blood clots 
on the surface of the lesser curvature. A subtotal palliative 
Billroth II resection was performed without preoperative 
chemotherapy. Pathology found an exophytic tumor with 
necrosis located in the antrum 5 cm in diameter. Gastric 
folds were smoothed as the tumor invaded through the 
seromuscular layer and infiltrated the perigastric adipose 
tissue as well as the duodenum. Metastatic infiltrates were 
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found in 11 of 13 identified local lymph nodes (diameter 
up to 1.5 cm) — stage pT4aN3a. 
Histological assessment showed a poorly differentiated 
adenocarcinoma with an infiltrate of osteoclast-like giant 
cells (Fig. 1). Neoplastic cells were positive for CK 7, AE1/
AE3+, EMA+/– and negative for vimentin, synaptophysin, 
CD 31, CD 20, CD 99, HCG, EBV (LMP-1) and Her-2, while 
OGCs were positive for CD68+ and lysozyme. Immunohi-
stochemical staining was performed using antibodies from 
Dako and Roche (for Her-2). The OGC were present both 
in the primary gastric adenocarcinoma and lymph node 
metastases. CD 3, CD 4 T-lymphoid cells infiltrates were 
observed in tumor stroma. 
A postoperative CT scan (April 2013) revealed a cancer 
infiltration of the pancreas head and enlargement of the 
paraaortic lymph nodes. Poor general condition (WHO 3), 
jaundice (serum bilirubin level 80–122 µmol/l) with elevated 
activities of GGTP (460–680 IU/l) and ALP (359–560 IU/l) 
precluded chemotherapy. There was rapid local progression 
with extensive perigastric involvement. The patient died 5 
months after surgery. 
Discussion
Gastric carcinomas with OGC are a heterogeneous group 
of tumors. Ushiku et al. described three distinct types of gastric 
carcinomas with OGC: lymphoepithelioma — like carcinoma 
(LELC), non-LELC, and giant cell tumor (GCT) [8]. According 
to the authors, the LELC type is associated with Epstein-Barr 
Virus (EBV) infection, that could be confirmed by RNA in situ 
hybridization (ISH) and granulomatous reaction with OGC, 
forming small clusters of epithelioid histiocytes or sarcoidal 
granuloma. In constrast, non-LELC cases are not associated 
with EBV infection or possibly loose viral DNA in the cancer pro-
gression [8]. In addition to OGC, infiltrations with neutrophils, 
macrophages and lymphoplasmacytic cells were reported. The 
GCT type is characterized by numerous OGC with metaplastic 
bone formation [8]. In most described cases, authors suggested 
a histocytic origin of OGC, due to the positive expression of 
CD68 [8, 9]. These cells can be found in tumor tissues, meta-
static lymph nodes and in the stroma. Presumably, OGC could 
be part of the immune response to tumor tissue antigens. An 
unanswered question is whether such neoplasms (with OGC 
infiltrates) are more aggressive than adenocarcinomas without 
Figure 1. Poorly differentiated adenocarcinoma of the stomach:
A: with multinucleated giant cells. H-E stain × 200; B: positive for cytokeratin CK7. IHC stain × 200; C: positive CD 68 staining on the OGC and 
stromal macrophages, IHC × 200; D: positive lysozyme staining in multinucleated giant cells. IHC × 100
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OGC. Some authors have suggested that the LELC subtype 
is associated with a better prognosis [10], however available 
literature reports cases with both good and poor prognosis 
(Tab. I). The average age was 69 years, which is close to the 
age of cancer patients without OGC cells (median age 68). 
The majority of cases (78%) was described in men. In 13 of 18 
cases the disease was diagnosed at the stage of loco-regional 
advanced disease. All described patients underwent surgery 
and most of them survived more than 12 months.
In the presented case, gastric cancer with OGC was poorly 
differentiated. It was characterized by rapid growth, early me-
tastasis and poor prognosis. The absence of EBV infection and 
lack of metaplastic bone formation units, negative staining for 
synaptophysin and infiltration by lymphocytic cells may suggest 
a non-LELC subtype. The rarity of this type neoplasm in clinical 
practice as well as very limited relevant literature data make 
it extremely difficult to arrive at universal conclusions about 
the prognosis in OGC gastric adenocarcinomas in comparison 
to other types of gastric carcinomas. Moreover, the function 
of OGC in tumor biology also remains unclear. This problem 
definitely needs further assessment on larger groups of patients.
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Table I. Summary of reported cases with gastric carcinoma with OCG (N = 18)
Age Gender Tumor Stage Tumor type Therapy Postoperative follow-up Ref.
81 Male T1b N0 M0 non-LELC Subtotal gastrectomy > 12 months [11]
69 Male T1 N0 M0 LELC Partial gastrectomy Unknown [8]
69 Male T3 N0 M0 LELC Distal gastrectomy Unknown [8]
50 Male T3 N0 M0 LELC Initial surgery > 3 months [12]
63 Male T2 N1 M0 LELC Subtotal gastrectomy > 120 months [13]
61 Male T2 N1 M0 LELC Subtotal gastrectomy + after 15 months [13]
76 Male T2 N1 M0 LELC Subtotal  gastrectomy + after 13 months [13]
71 Male T2 N1 M0 LELC Total gastrectomy > 57 months [8]
65 Male T2 N1 M0 non-LELC Distal gastrectomy > 102 months [8]
64 Male T3 N1 M0 LELC Total gastrectomy > 7 months [8]
86 Male T4 N1 M0 GCT Palliative gastrectomy Unknown [8]
84 Male T2 N1 M0 non-LELC Distal gastrectomy > 74 months [8]
64 Female T1 N2 M0 non-LELC Distal gastrectomy > 12 months [10]
53 Male T2 N2 M0 LELC Subtotal gastrectomy + after 24 months [13]
70 Female T3 N2 M0 LELC Total gastrectomy Unknown [9]
78 Male T3 N2 M1 non-LELC Total gastrectomy > 6 months [14]
73 Female pT3 N3a M1 (liver) GCT Initial surgery Unknown/ Fast PD [15]
75 Female T4a N3a M1 (lymph nodes) non-LELC Subtotal gastrectomy + after 5 months Current case
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Appendix
Figure 2. Poorly differentiated adenocarcinoma of the stomach (H&E 200 um)
